NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].
Show detailsOVERVIEW
Several naturally occurring compounds with antibiotic activity also have potent antitumor activity and were developed as anticancer agents. These cytotoxic antibiotics are often grouped together, even though they have diverse mechanisms of action, widely different indications, a range of efficacies and distinctive toxicities. The cytotoxic antibiotics in current use in the United States include (with trade name and year of approval): bleomycin (Blenoxane, 1973), dactinomycin (Cosmegen, 1964), daunorubicin (Cerubidine, 1979), doxorubicin (Adriamycin, 1974), epirubicin (Ellence, 1999), idarubicin (Idamycin, 1990), plicamycin (previously known as mithramycin, still experimental), mitomycin (Mutamycin, 2002) and mitoxantrone (Novantrone, 1987). A discussion of the mechanism of action, current use and hepatotoxicity, along with structural information and references of these drugs, are provided for each agent individually. The anthracycline antibiotics include daunorubicin, doxorubicin, epirubicin and idarubicin (which are discussed together) and mitoxantrone, which is an anthracycline analog and discussed separately.
Most of the cytotoxic antibiotics used in cancer chemotherapy have been implicated in cases of drug induced liver injury, generally associated with the use of high doses and with either direct hepatocellular injury or sinusoidal obstruction syndrome (from direct sinusoid cell injury). Because they are typically used in combination with other antineoplastic agents, it is often difficult to identify which is responsible for the liver injury.
Drug Class: Antineoplastic Agents
The cytotoxic antibiotics discussed in LiverTox include:
- Review Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.[J Clin Pharmacol. 1986]Review Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.Wadler S, Fuks JZ, Wiernik PH. J Clin Pharmacol. 1986 Sep-Oct; 26(7):491-509.
- Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.[Cancer Chemother Pharmacol. 1992]Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.Kuffel MJ, Reid JM, Ames MM. Cancer Chemother Pharmacol. 1992; 30(1):51-7.
- Review Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.[Drugs Exp Clin Res. 1986]Review Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.Hurteloup P, Ganzina F. Drugs Exp Clin Res. 1986; 12(1-3):233-46.
- Review New anthracycline antitumor antibiotics.[Crit Rev Oncol Hematol. 1991]Review New anthracycline antitumor antibiotics.Muggia FM, Green MD. Crit Rev Oncol Hematol. 1991; 11(1):43-64.
- Review [Pharmacokinetics of new anthracyclines].[Bull Cancer. 1988]Review [Pharmacokinetics of new anthracyclines].Robert J. Bull Cancer. 1988; 75(2):167-74.
- Cytotoxic Antibiotics - LiverToxCytotoxic Antibiotics - LiverTox
Your browsing activity is empty.
Activity recording is turned off.
See more...